



2ND SCIENTIFIC SYMPOSIUM OF THE WBMT

Salvador -Bahia, Brazil



WWW.WBMT.ORG

5th October 2013

FINAL PROGRAM



NOW AVAILABLE AS
CE-MARKED
MEDICAL DEVICE
IN EUROPE

The CliniMACS Prodigy®

Moving cell manufacturing towards the next level

Automated cell processing from cell sample to final product

- Flexible programming options
- MACS® Cell Separation
- Cell washing procedures
- Fully automated, closed system
- Density gradient fractionation
- Optimized cell culture

Miltenyi Biotec provides products and services worldwide.
Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

► clinimacs-prodigy.com

The CliniMACS® System components, Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components, including the CliniMACS Reagents, are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). In the USA, the components of the CliniMACS Prodigy line are for research use only and not for human therapeutic or diagnostic use. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use. MACS, CliniMACS, and CliniMACS Prodigy are registered trademarks of Miltenyi Biotec GmbH. Copyright © 2013 Miltenyi Biotec GmbH. All rights reserved.

DEAR FRIENDS,


I warmly welcome you to the second Scientific Symposium of the Worldwide Network for Blood and Marrow Transplantation (WBMT) in Salvador, Brazil. This is a memorable occasion, which represents a big effort of many individuals and societies around the world to continue a series of events aiming at helping countries with restricted resources and transplantation activity. It is certainly unique that many societies active in the field of Haematopoietic Stem Cell Transplantation (HSCT) around the world collaborate under the umbrella of the WBMT to offer their decades of experience to improve and build up programs for a curative treatment for many haematological and non-haematological diseases. In line with the guiding principles of the WHO, we will discuss with delegates of Latin American countries, but also with delegates from North America, Asia Pacific, Europe and Africa, important points on how to optimize or establish a stem cell transplantation program, on current indications for HSCT, donor selection, graft processing, developing an outcome database and the need for a global accreditation system. Since HSCT is a very costly procedure, it is essential to discuss these items under the aspects of restricted resources representing a challenge for presenter and audience.

The Scientific Symposium will be unique also from another standpoint. The guiding principles of the WHO declare regulation of transplantation on a national level as a governmental responsibility. One of the goals of this Scientific Symposium is to encourage the integration of haematopoietic HSCT within the Healthcare Policy of developing countries. This cannot be done without the active participation of politicians, national authorities and representatives of regulatory bodies, who responded with enthusiasm and will participate actively during this event.

With this Scientific Symposium, the WBMT and its 21 Member Societies are making a further step towards excellence in stem cell transplantation around the world. The 2006 global survey published in JAMA, the first meeting in Hanoi, Vietnam (in 2011) and the global survey recently published in Haematologica, as well as the foundation of the African Society for Blood and Marrow Transplantation (AFBMT), were first steps towards this aim. Future projects include the creation of a global transplant center number and a donor outcome registry, just to mention a few. All these and many more activities are essential for the mission of the WBMT and will require efforts from all of us and the participation of many colleagues and experts around the world.

Let me express my admiration and gratefulness to all people involved in this Scientific Symposium starting with Prof. Luis Bouzas, Adriana Seber, German Espino and Marco Salvino, and all the people of the Latin American Blood and Marrow Transplant (LABMT) group. My thanks also to all the WBMT Standing Committee Chairs, the Executive Organizing and Program Planning Committees, and especially to Marcelo Pasquini, who in many long lasting telephone conferences were able to create an outstanding program. I also appreciate administrative support provided by Paula Watry of the CIBMTR. Without the participation of the WMDA, EBMT, CIBMTR, APBMT, EMBMT and LABMT, this event would not be possible. I am personally impressed by the enthusiasm and the willingness of many people to pursue in this effort and wish you all the best for this Scientific Symposium

Sincerely



*Dietger Niederwieser for the Executive Committee of the WBMT
Non-Government Organization (NGO) in official relations with the World Health Organization*

DISTINGUISHED DELEGATES AND GUESTS,

It is a great pleasure to welcome you all here to Salvador for the 2nd Global Scientific Symposium on Haematopoietic Stem Cells Transplantation (HSCT) in Emerging Countries.

We would like to genuinely thank the Worldwide Network for Blood & Marrow Transplantation (WBMT) for mentoring this important and fascinating Scientific Symposium.


This Scientific Symposium aims to provide the opportunity to discuss the clinical, political and administrative requirements necessary to promote the development of stem cell transplantation activities in emerging areas and countries with limited resources. In Hanoi, it was shown that this is possible through the incentive and collaboration of all countries and organizations involved.

In addition to the stimulating intellectual and professional discussions and talks promoted by the experts, delegates will have the chance to experience Salvador, which was chosen to host this workshop because of its strategic location, economic importance in the northern areas of Brazil, and its need of a robust transplant program. Salvador is also close to PanAmazonic and other Latin America countries, and shares with them many social and economic issues. We trust that the result of this Scientific Symposium will be very useful to all participants.

We are greatly honored and privileged to have you all here and wish you a successful experience and a pleasant stay in Salvador.




Luis Bouzas
Interim President/LABMT



Adriana Seber
Interim Secretary/LABMT



German Espino
Co-Host/Panama



Marco Salvino
Co-Host Brazil

SATURDAY - 5TH OCTOBER 2013

WBMT SYMPOSIUM IN SALVADOR 2013

8.30 – 10.00 OPTIMAL STEM CELL SOURCE IN ALLOGENEIC HSCT

CHAIRS:

Dennis Confer, Minneapolis, USA;
Marco Aurélio Salvino, Salvador, Brazil

8.30 - 9.00 BONE MARROW VS. PERIPHERAL BLOOD

Daniel Weisdorf, Minneapolis, USA

9.00 - 9.30 HSCT WITH CORD BLOOD STEM CELLS

Vanderson Rocha, United Kingdom

9.30 - 10:00 HAPLO-IDENTICAL HSCT FROM FAMILY MEMBERS

Julia Palma, Chile

10:00 - 10:30 BREAK

10.30 - 12.00 COMPLICATIONS OF HSCT

CHAIRS:

Dietger Niederwieser, Leipzig, Germany;
German Espino, Panama City, Panama

10.30 - 11.00 GRAFT FAILURE AFTER HSCT

Vanderson Rocha, Oxford, United Kingdom

11:00 - 11:30 COMPLICATIONS AFTER HSCT

Dietger Niederwieser, Leipzig, Germany

11:30 - 12:00 GRAFT-VERSUS-HOST DISEASE

Hildegard Greinix, Vienna, Austria

SATURDAY - 5TH OCTOBER 2013 (CONTINUED)

**12.00 - 14.00 LUNCH SYMPOSIUM SPONSORED BY A GRANT FROM THERAKOS
IMMUNOMODULATORY TREATMENT FOR GRAFT VERSUS HOST DISEASES**

.....
14.00 - 15.00 HSCT IN NON-MALIGNANT DISEASES
.....

CHAIRS:

Yoshihisa Kodera, Nagoya, Japan;
Adriana Seber, Sao Paulo, Brazil

14.00 - 14.20 HSCT FOR BONE MARROW FAILURES

Carmem Bonfim, Curitiba, Brazil

14.20 - 14.40 HSCT IN HEMOGLOBINOPATHIES

Belinda Simoes, Ribeirão Preto, Brazil

14.40 - 15.00 HSCT IN AUTOIMMUNE DISEASES

Belinda Simoes, Ribeirão Preto, Brazil

15.00 - 15.30 BREAK

.....
15.30 - 17.00 HSCT IN MALIGNANT DISEASE
.....

CHAIRS:

Marcelo Pasquini, Milwaukee, USA
Luis Bouzas, Rio de Janeiro, Brazil

15.30 - 16.00 HSCT IN LEUKAEMIA

Dietger Niederwieser, Leipzig, Germany

16.00 - 16.30 HSCT IN LYMPHOMA

Gregorio Jaimovich, Buenos Aires, Argentina

16.30 - 17.00 HSCT IN MYELOMA

Marcelo Pasquini, Milwaukee, USA

.....
17.00 - 17.30 LONG TERM COMPLICATIONS
.....

LATE EFFECTS

André Tichelli, Basel, Switzerland

GENERAL INFORMATION

DATE

5 October 2013

VENUE

*Hotel Stella Maris
Gran Hotel Stella Maris
Resort & Convention – Sol Express
Praça Stella Maris, 200 Stella Maris
www.solexpress.com.br*

CONGRESS LANGUAGE

English is the official language of the WBMT 2013 Workshop. No simultaneous translation will be provided.

INSURANCE AND LIABILITY

It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. WBMT and MCI as organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the congress participants and accompanying persons.

REGISTRATION AND HOTEL ACCOMMODATION SEE HOMEPAGE

www.wbmt.org

CONTACT

*For any question related to the registration and/or hotel accommodation, please contact MCI.
Tel +41 22 33 99 599
Fax +41 22 33 99 631
E-mail: wbmt2013reg@mci-group.com*

OFFICE HOURS:

*Monday to Friday
9:00 to 18:00
CET - Central European Time
(our offices are open on regular business days with the exception of public holidays)*

SPONSORS

BIOSAFE SA

CYTOLON AG

FRESENIUS BIOTECH GMBH

GENTIUM

HISTOGENETICS

MILTENYI BIOTEC GMBH

MOCHIDA PHARMA. JAPAN

NIPPON KAYAKU JAPAN

NOVARTIS PHARMA. JAPAN

ONTIME COURIER

SANOFI ASIA

THERAKOS, INC

The essential choice in cell processing

Swiss made quality & service

New Protocol for Transplant Center – SmartRedux:


- Volume and time reduction
- RBC and Plasma depletion
- Minimize the risks associated with ABO incompatibility
- Concentration of TNC



SmartRedux features	
Processed initial volume	30 to 3300 ml
Selectable final volume	up to 1500 ml
Processing time	~20 minutes/cycle
TNC recovery	>75% (linked to the applied concentration ratio)

Nova Sucursal - Nueva Sucursal:

Biosafe Latin America
 Av. Chedid Jafet, 222 - 5th floor - Block D – Office 505
 Vila Olimpia – ZIP 04551-065 – Sao Paulo - SP – Brasil
 T.: +55 11 2655 1731 M.: +55 11 99326 5454
 info@biosafe.ch – www.biosafe.ch



HISTOGENETICS

HIGH VOLUME HLA SEQUENCE BASED TYPING (SBT) WORLD WIDE



CUSTOMIZED TYPING SERVICES

HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DRB3/4/5
HLA-DQA1, HLA-DQB1, HLA-DPA1, HLA-DPB1, KIR

OVER 13 MILLION SBT PERFORMED

WWW.HISTOGENETICS.COM

300 Executive Blvd. Ossining, NY 10562. USA.
Phone 914-762-0300 Fax 914-762-4441